fotemustine has been researched along with Bone Marrow Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bensadoun, JR; Bonneterre, J; Bourdin, S; Clavel, M; Cupissol, D; de Gislain, C; Delaunay, MM; Guillot, B; Hauschild, A; Lesimple, T; Mohr, P; Mornex, F; Mousseau, M; Nguyen, BB; Thomas, L; Tilgen, W; Ulrich, J | 1 |
| Antoine, E; Auclerc, G; Benhammouda, A; Bizzari, JP; Borel, C; Paraiso, D; Petit, T; Rixe, O; Soubrane, C; Weil, M | 1 |
2 trial(s) available for fotemustine and Bone Marrow Diseases
| Article | Year |
|---|---|
[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma].
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Diseases; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Disease Progression; Female; Humans; Life Tables; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Survival Analysis; Treatment Outcome | 2003 |
Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Risk; Salvage Therapy; Survival Rate; Treatment Outcome; Vindesine | 1995 |